Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
GlycoMimetics Inc Market Cap
Based on ratings from 1 stock analysts, the GlycoMimetics Inc stock price is expected to increase by 244.83% in 12 months. This is calculated by using the average 12-month stock price forecast for GlycoMimetics Inc. The lowest target is $1 and the highest is $1. Please note analyst price targets are not guaranteed and could be missed completely.
About 1 Wall Street analysts have assigned GLYC 1 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect GlycoMimetics Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on GLYC. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of GLYC.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Boris Peaker TD Cowen | Hold | Downgrade | Jul 26, 2024 | |
| Edward White HC Wainwright & Co. | Neutral | Reiterates | Jun 4, 2024 | |
| Edward White HC Wainwright & Co. | Neutral | Downgrade | May 6, 2024 | |
| Edward White HC Wainwright & Co. | Buy | $8 | Maintains | Mar 27, 2024 |
| Zegbeh Jallah Capital One | Overweight | $12 | Initiates | Dec 22, 2023 |
| Edward White HC Wainwright & Co. | Buy | $8 | Reiterates | Aug 3, 2023 |
| Edward White HC Wainwright & Co. | Buy | $8 | Reiterates | Jun 15, 2023 |
| Edward White HC Wainwright & Co. | Buy | $8 | Reiterates | May 4, 2023 |
| Edward White HC Wainwright & Co. | Buy | $8 | Reiterates | Mar 30, 2023 |
| Edward White HC Wainwright & Co. | Buy | $8 | Maintains | Feb 16, 2023 |
| Edward White HC Wainwright & Co. | Buy | $13 | Maintains | Aug 4, 2022 |
| Roger Song Jefferies | Buy | $4 | Upgrade | Nov 12, 2021 |
Roth Capital | Buy | $15 | Maintains | Dec 8, 2020 |
HC Wainwright & Co. | Buy | $15 | Maintains | Jul 31, 2020 |
| Edward White HC Wainwright & Co. | Buy | $16 | Reiterates | Mar 2, 2020 |
H.C. Wainwright | Buy | Reiterates | Mar 2, 2020 | |
Roth Capital | Buy | Initiates | Nov 14, 2019 | |
Piper Jaffray | Neutral | Downgrade | Aug 5, 2019 | |
SunTrust Robinson Humphrey | Hold | $5 | Downgrade | Aug 5, 2019 |
Jefferies | Hold | Downgrade | Aug 5, 2019 |
When did it IPO
2014
Staff Count
35
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Harout Semerjian
Market Cap
$19.0M
In 2023, GLYC generated $10,000 in revenue, which was a decrease of -86.67% from the previous year. This can be seen as a signal that GLYC's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 12 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Crescent Biopharma will present its lead program, CR-001, a bispecific antibody for solid tumors, at the Jefferies London Healthcare Conference on November 19, 2024.
Why It Matters - Crescent Biopharma's presentation on CR-001 at a major healthcare conference may attract investor interest, signaling potential advancements in cancer treatment and future revenue opportunities.
Tue, 05 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Monteverde & Associates is investigating GlycoMimetics, Inc. (NASDAQ: GLYC) regarding its merger with First Crescent Biopharma, which will result in GlycoMimetics shareholders owning 3.1% of the new entity.
Why It Matters - The proposed merger significantly dilutes GlycoMimetics shareholders' ownership, raising concerns about their financial stake and potential value in the combined entity.
Wed, 06 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - GlycoMimetics, Inc. (Nasdaq: GLYC) announced that data on uproleselan for acute myeloid leukemia will be presented at the ASH Annual Meeting in San Diego, December 7-10, 2024.
Why It Matters - Acceptance of clinical trial data for uproleselan at a major hematology conference can boost GlycoMimetics' credibility, attract investor interest, and potentially impact stock performance.
Sun, 03 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Monteverde & Associates is investigating GlycoMimetics, Inc. (NASDAQ: GLYC) regarding its proposed merger with First Crescent Biopharma, which will result in GlycoMimetics shareholders owning 3.1% of the new entity.
Why It Matters - The merger significantly dilutes GlycoMimetics shareholders, limiting their ownership to 3.1%, which may impact stock value and investor sentiment regarding the deal's fairness.
Thu, 31 Oct 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Kahn Swick & Foti, LLC is investigating the proposed merger between GlycoMimetics, Inc. and Crescent Biopharma, Inc., focusing on the adequacy of the merger terms for shareholders.
Why It Matters - Concerns over the GlycoMimetics and Crescent Biopharma merger could affect shareholder confidence and stock performance, as investigations may indicate potential issues with the deal's fairness.
Tue, 29 Oct 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - GlycoMimetics, Inc. has announced an acquisition of Crescent Biopharma, Inc., focusing on oncology therapeutics. Post-acquisition, the company will operate under Crescent Biopharma's name.
Why It Matters - GlycoMimetics' acquisition of Crescent Biopharma signals a strategic shift towards oncology, potentially enhancing its product pipeline and market position, affecting investor sentiment and stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
